| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Top7 or 10 Tips > Chairing A Meeting For Business - Top Ten Tips |
|
Useful Advices - Chairing A Meeting For Business - Top Ten Tips
• Make sure you have clear aims and objectives for the meeting – many meetings are held in According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product businesses for no better reason than that that’s what they’ve always done each month. Tha ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in t’s just not effective. • Make sure the meeting has an agenda and that this has been lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. issued to all participants in advance • Make sure you have allocated a dedicated minu here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe te taker to the meeting and that that person understands their role • If you have a l d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro arge number of participants make simple rules and list them before you start e.g. everyone ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc must put up their hand and be indicated by the chair before speaking (to stop people all easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi peaking at once.) • If this is a follow-up or on-going meeting make sure that the fir nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically st point on the agenda is going through the action points listed on the previous minutes. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ • If actions have not been carried out this may or may not be the time to find out w ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi hy. If there is a later point on the agenda that will explain why an action has not been c ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a arried out, state firmly that this point will be discussed on agenda point 5 (or whatever dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod the relevant number is) • Keep people on topic. It’s easy for discussions to become cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin impassioned and roam off to other topics. Firmly state that these issues will either be di tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen cussed later in the meeting or are not relevant to the meeting. • Don’t lose your tem t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel per! It is vital that the chair keeps a cool head in order to maintain order in the meetin ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust g. • At the end of the meeting ask the minute taker if s/he has any points that need y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products clarifying. This gives the minute taker an opportunity to check details on the spot, and m . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de inutes can then be issued more quickly. • Check the meeting minutes before issuing t elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip hem, or having them issued, to the other participants and any team members who were absent tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Teaching The Big Boys To Think Small History Of Business Administration Education What Do You Do? Ways to Make Sure that your Clients don't Buy Elsewhere
|